LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ

Creative Commons License

Rutten G. E. H. M., Tack C. J., Pieber T. R., ÇÖMLEKÇİ A., Orsted D. D., Baeres F. M. M., ...Daha Fazla

DIABETOLOGY & METABOLIC SYNDROME, cilt.8, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1186/s13098-016-0153-5
  • Dergi Adı: DIABETOLOGY & METABOLIC SYNDROME
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Type 2 diabetes, External validity, Generalizability, Cardiovascular outcome trial, Heterogeneity, RANDOMIZED CONTROLLED-TRIALS, INDIVIDUAL PATIENTS, EXTERNAL VALIDITY, VASCULAR-DISEASE, MANAGEMENT, OUTCOMES
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aims: To determine whether US and European participants in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial differ regarding risk factors for cardiovascular mortality and morbidity.